Cargando…

Serum IFN-γ-induced protein 10 (IP-10) as a biomarker for severity of acute respiratory infection in healthy adults

BACKGROUND: The inflammatory chemokine, interferon-gamma inducible protein of 10 kDa (IP-10), is a biomarker associated with several conditions. OBJECTIVES: This study investigated serum concentrations of IP-10 in healthy individuals who developed acute respiratory infection (ARI). The hypothesis is...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayney, Mary S., Henriquez, Kelsey M., Barnet, Jodi H., Ewers, Tola, Champion, Heather M., Flannery, Sean, Barrett, Bruce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408957/
https://www.ncbi.nlm.nih.gov/pubmed/28334685
http://dx.doi.org/10.1016/j.jcv.2017.03.003
_version_ 1783232389224333312
author Hayney, Mary S.
Henriquez, Kelsey M.
Barnet, Jodi H.
Ewers, Tola
Champion, Heather M.
Flannery, Sean
Barrett, Bruce
author_facet Hayney, Mary S.
Henriquez, Kelsey M.
Barnet, Jodi H.
Ewers, Tola
Champion, Heather M.
Flannery, Sean
Barrett, Bruce
author_sort Hayney, Mary S.
collection PubMed
description BACKGROUND: The inflammatory chemokine, interferon-gamma inducible protein of 10 kDa (IP-10), is a biomarker associated with several conditions. OBJECTIVES: This study investigated serum concentrations of IP-10 in healthy individuals who developed acute respiratory infection (ARI). The hypothesis is that serum IP-10 concentrations correlate with ARI severity and detection of viral pathogens. STUDY DESIGN: Data come from a randomized controlled trial measuring the effects of mindfulness meditation or exercise on ARI (Clinical Trials ID: NCT01654289). Healthy adults ages 30–69 were followed for a single season for ARI incidence and severity. This trial is ongoing, and the investigators are still blinded. When a participant reported ARI symptoms, nasal swab and lavage for PCR-based viral identification and blood samples were collected within the first 72 h of ARI symptoms. Serum IP-10 concentrations were measured by ELISA (R&D Systems, Inc., Quantikine ELISA, Minneapolis, MN). ARI severity was measured using the validated Wisconsin Upper Respiratory Symptom Survey (WURSS-24) until the ARI episode resolved. RESULTS: Serum IP-10 concentrations from 225 ARI episodes correlated with ARI global severity (rho 0.28 [95% CI: 0.15–0.39]; p < 0.001). IP-10 concentrations were higher with an ARI in which a viral pathogen was detected compared to no viral pathogen detected (median 366 pg/ml [IQR: 227–486] vs 163 pg/ml [IQR: 127–295], p < 0.0001). Influenza infections had higher IP-10 concentrations than coronavirus, enterovirus or rhinovirus, and paramyxovirus. CONCLUSION: Serum IP-10 concentration correlates with ARI global severity. Also, IP-10 concentration measured early in the course of the ARI correlates with the daily severity, duration, and illness symptoms.
format Online
Article
Text
id pubmed-5408957
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-54089572018-05-01 Serum IFN-γ-induced protein 10 (IP-10) as a biomarker for severity of acute respiratory infection in healthy adults Hayney, Mary S. Henriquez, Kelsey M. Barnet, Jodi H. Ewers, Tola Champion, Heather M. Flannery, Sean Barrett, Bruce J Clin Virol Article BACKGROUND: The inflammatory chemokine, interferon-gamma inducible protein of 10 kDa (IP-10), is a biomarker associated with several conditions. OBJECTIVES: This study investigated serum concentrations of IP-10 in healthy individuals who developed acute respiratory infection (ARI). The hypothesis is that serum IP-10 concentrations correlate with ARI severity and detection of viral pathogens. STUDY DESIGN: Data come from a randomized controlled trial measuring the effects of mindfulness meditation or exercise on ARI (Clinical Trials ID: NCT01654289). Healthy adults ages 30–69 were followed for a single season for ARI incidence and severity. This trial is ongoing, and the investigators are still blinded. When a participant reported ARI symptoms, nasal swab and lavage for PCR-based viral identification and blood samples were collected within the first 72 h of ARI symptoms. Serum IP-10 concentrations were measured by ELISA (R&D Systems, Inc., Quantikine ELISA, Minneapolis, MN). ARI severity was measured using the validated Wisconsin Upper Respiratory Symptom Survey (WURSS-24) until the ARI episode resolved. RESULTS: Serum IP-10 concentrations from 225 ARI episodes correlated with ARI global severity (rho 0.28 [95% CI: 0.15–0.39]; p < 0.001). IP-10 concentrations were higher with an ARI in which a viral pathogen was detected compared to no viral pathogen detected (median 366 pg/ml [IQR: 227–486] vs 163 pg/ml [IQR: 127–295], p < 0.0001). Influenza infections had higher IP-10 concentrations than coronavirus, enterovirus or rhinovirus, and paramyxovirus. CONCLUSION: Serum IP-10 concentration correlates with ARI global severity. Also, IP-10 concentration measured early in the course of the ARI correlates with the daily severity, duration, and illness symptoms. Elsevier B.V. 2017-05 2017-03-16 /pmc/articles/PMC5408957/ /pubmed/28334685 http://dx.doi.org/10.1016/j.jcv.2017.03.003 Text en © 2017 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Hayney, Mary S.
Henriquez, Kelsey M.
Barnet, Jodi H.
Ewers, Tola
Champion, Heather M.
Flannery, Sean
Barrett, Bruce
Serum IFN-γ-induced protein 10 (IP-10) as a biomarker for severity of acute respiratory infection in healthy adults
title Serum IFN-γ-induced protein 10 (IP-10) as a biomarker for severity of acute respiratory infection in healthy adults
title_full Serum IFN-γ-induced protein 10 (IP-10) as a biomarker for severity of acute respiratory infection in healthy adults
title_fullStr Serum IFN-γ-induced protein 10 (IP-10) as a biomarker for severity of acute respiratory infection in healthy adults
title_full_unstemmed Serum IFN-γ-induced protein 10 (IP-10) as a biomarker for severity of acute respiratory infection in healthy adults
title_short Serum IFN-γ-induced protein 10 (IP-10) as a biomarker for severity of acute respiratory infection in healthy adults
title_sort serum ifn-γ-induced protein 10 (ip-10) as a biomarker for severity of acute respiratory infection in healthy adults
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408957/
https://www.ncbi.nlm.nih.gov/pubmed/28334685
http://dx.doi.org/10.1016/j.jcv.2017.03.003
work_keys_str_mv AT hayneymarys serumifnginducedprotein10ip10asabiomarkerforseverityofacuterespiratoryinfectioninhealthyadults
AT henriquezkelseym serumifnginducedprotein10ip10asabiomarkerforseverityofacuterespiratoryinfectioninhealthyadults
AT barnetjodih serumifnginducedprotein10ip10asabiomarkerforseverityofacuterespiratoryinfectioninhealthyadults
AT ewerstola serumifnginducedprotein10ip10asabiomarkerforseverityofacuterespiratoryinfectioninhealthyadults
AT championheatherm serumifnginducedprotein10ip10asabiomarkerforseverityofacuterespiratoryinfectioninhealthyadults
AT flannerysean serumifnginducedprotein10ip10asabiomarkerforseverityofacuterespiratoryinfectioninhealthyadults
AT barrettbruce serumifnginducedprotein10ip10asabiomarkerforseverityofacuterespiratoryinfectioninhealthyadults